Suppr超能文献

贝赫切特病(BD)的临床特征、治疗特点和结局:来自卡纳塔克邦风湿病协会(KRA)的回顾性队列研究。

Clinical profiling, treatment characteristics and outcome in Behcet's Disease (BD)-A retrospective cohort study from Karnataka Rheumatology Association (KRA).

机构信息

Divisha Arthritis and Medical Center, Bengaluru, India.

Department of Clinical Immunology and Rheumatology, St. John's Medical College Hospital, Sarjapur Road, Bengaluru, India, 560034.

出版信息

Clin Rheumatol. 2024 Oct;43(10):3223-3230. doi: 10.1007/s10067-024-07089-x. Epub 2024 Aug 3.

Abstract

BACKGROUND

Behcet's disease (BD) has a heterogeneous and unpredictable phenotype that differs in various geographical areas.

OBJECTIVE

To describe the clinical phenotype & outcome of Behcet's disease(BD) from Karnataka, India and compare them with large cohorts from endemic regions.

METHODS

Databases of practising rheumatologists from Karnataka were reviewed to retrieve clinical characteristics, course of illness, prescribing information and outcome at last follow-up of patients clinically diagnosed as BD. The classification criteria, namely revised International criteria for Behcet's disease (rICBD) and International study group (ISG) criteria were applied. Outcome was defined as complete or partial remission, persistent disease or relapse.

RESULTS

We included 72 patients, equal gender distribution and mean age 37.4 ± 12.8 years from 8 rheumatology centres. Commonest presentations were recurrent oral aphthosis 58(80.6%), genital ulcers 36(50%) and ocular manifestations 40(55.6%). Three-quarters [51/72(70.8%)] fulfilled rICBD criteria whereas only half [36/72(50%)] fulfilled ISG criteria. Apart from glucocorticoids [53/72(73.6%)], frequently prescribed therapies were colchicine 39(54.2%) and azathioprine 35(48.6%). Eleven-patients received biologics(anti-TNF-α) and JAK inhibitors to treat severe organ involvement. HLA-B*51 and pathergy tests were positive in 27/45(60%) and 12/34(35.3%) patients respectively. Outcomes were documented in 94.4%(68/72) patients at median follow-up of 24 (12;36) months. Majority [46/68(67.6%)] had complete remission, 17/68(25%) had partial remission, 4/68(5.9%) had persistent while 1/68(1.5%) had relapsing course.

CONCLUSION

Majority of BD patients had orogenital aphthosis and ocular manifestations and an excellent response to treatment. Key Points • In our region, Behçet's Disease primarily manifests with recurrent oral aphthae and ocular involvement, with comparatively lower incidence of severe genital ulcers and neurological involvement than in endemic regions. • Apart from glucocorticoids, colchicine and azathioprine are the most commonly used agents. Biologics and JAK inhibitors are prescribed infrequently, primarily in cases of severe organ involvement. • A significant proportion of patients achieved either complete or partial remission during follow-up, with no observed mortality suggesting a milder disease course and better outcome compared to endemic regions. • Gender, HLA-B*51 status, and pathergy response did not exert any significant influence on the clinical profile or outcome in BD patients in Karnataka.

摘要

背景

白塞病(BD)具有异质性和不可预测的表型,在不同的地理区域表现不同。

目的

描述来自印度卡纳塔克邦的白塞病(BD)的临床表型和结局,并将其与来自流行地区的大型队列进行比较。

方法

对卡纳塔克邦执业风湿病学家的数据库进行了回顾,以检索临床诊断为 BD 的患者的临床特征、疾病过程、用药信息和最后一次随访时的结局。应用了修订的国际白塞病分类标准(rICBD)和国际研究组(ISG)标准。结局定义为完全或部分缓解、持续疾病或复发。

结果

我们纳入了来自 8 个风湿病中心的 72 名患者,男女比例均等,平均年龄为 37.4±12.8 岁。最常见的表现是复发性口腔阿弗他溃疡 58 例(80.6%)、生殖器溃疡 36 例(50%)和眼部表现 40 例(55.6%)。72 例患者中有四分之三[51/72(70.8%)]符合 rICBD 标准,而只有一半[36/72(50%)]符合 ISG 标准。除了糖皮质激素[53/72(73.6%)]外,经常使用的治疗药物还包括秋水仙碱 39 例(54.2%)和硫唑嘌呤 35 例(48.6%)。11 名患者接受生物制剂(抗 TNF-α)和 JAK 抑制剂治疗严重的器官受累。在 45 名患者中有 27 名(60%)和在 34 名患者中有 12 名(35.3%)HLA-B*51 和 PATHERGY 试验阳性。在中位随访 24(12;36)个月时,记录了 94.4%(68/72)患者的结局。大多数[46/68(67.6%)]患者完全缓解,17/68(25%)患者部分缓解,4/68(5.9%)患者持续缓解,1/68(1.5%)患者复发。

结论

在我们的地区,BD 患者主要表现为复发性口腔阿弗他溃疡和眼部受累,治疗反应良好。主要观察结果:在本地区,白塞病主要表现为复发性口腔阿弗他溃疡和眼部受累,与流行地区相比,生殖器溃疡和神经系统受累的严重程度较低。除了糖皮质激素外,秋水仙碱和硫唑嘌呤是最常用的药物。生物制剂和 JAK 抑制剂很少使用,主要用于严重器官受累的病例。在随访期间,相当一部分患者达到完全或部分缓解,没有观察到死亡,这表明与流行地区相比,疾病过程较轻,结局较好。在卡纳塔克邦的 BD 患者中,性别、HLA-B*51 状态和 PATHERGY 反应对临床特征或结局没有显著影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验